Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 15 results:
Author Title Type [ Year] Filters: Author is Katsiki, Niki and Keyword is Risk Factors [Clear All Filters]
Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?.
Curr Vasc Pharmacol. 17(6), 564-572.
(2019). Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus..
Curr Pharm Des. 25(18), 2051-2059.
(2019). Exploring the Management of Statin Intolerant Patients: 2016 and Beyond..
Curr Vasc Pharmacol. 14(6), 523-533.
(2016). Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update..
World J Gastroenterol. 21(22), 6820-34.
(2015). Health benefits of the Mediterranean Diet: an update of research over the last 5 years..
Angiology. 66(4), 304-18.
(2015). Achieving lipid targets in primary care settings..
Curr Med Res Opin. 30(10), 1971-4.
(2014). Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview..
Curr Vasc Pharmacol. 12(4), 627-41.
(2014). Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors..
Curr Pharm Des. 20(40), 6215-9.
(2014). Should we expand the concept of coronary heart disease equivalents?.
Curr Opin Cardiol. 29(4), 389-95.
(2014). Metabolic syndrome and arterial stiffness: the past, the present and the future..
J Cardiovasc Med (Hagerstown). 14(10), 687-9.
(2013). Statins and nonalcoholic fatty liver disease: a bright future?.
Expert Opin Investig Drugs. 22(9), 1089-93.
(2013). The effects of incretins on energy homeostasis: physiology and implications for the treatment of type 2 diabetes mellitus and obesity..
Curr Vasc Pharmacol. 10(6), 781-91.
(2012). Should raising high-density lipoprotein cholesterol be a matter of debate?.
J Cardiovasc Med (Hagerstown). 13(4), 254-9.
(2012). Stage of chronic kidney disease and severity of coronary heart disease manifestation..
Expert Opin Pharmacother. 13(4), 457-60.
(2012). Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?.
Curr Vasc Pharmacol. 9(6), 698-705.
(2011).